Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of JNJ-79635322 versus teclistamab in relapsed or refractory multiple myeloma
ChiCTR2600133767Phase 3Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of ramantamig and teclistamab in multiple myeloma (MM) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Overall response rate, Very good partial response or better and 2 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
ramantamigteclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2600133767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133767.